Healthcare
Revolution Medicines, Inc. Warrant(RVMDW)
Live Price
Offline$1.88
+0.00% today
Window Change
+693.58%
Window
Jun 23, 2025 โ May 15, 2026
- Market Cap
- $31.44B
- Revenue Growth
- 0.0%
- EPS Growth
- -66.2%
- Dividend Yield
- 0.0%
Coverage: 227 bars ยท Jun 23, 2025 โ May 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Revolution Medicines, Inc. Warrant (RVMDW) is a Healthcare stock with a market cap of $31.44B and listed on NASDAQ. The stock last traded around $1.88 and up 693.6% across the available one-year price window (Jun 23, 2025 โ May 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -66.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -66.2%, free cash flow -60.9% with operating margin 0.0% and ROIC -56.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RVMDW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -66.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged -3.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +0.0% | โ | โ |
2026 Feb 25, 2026 | -17.6% | +6.9% | -3.0% | -18.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVMDW
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RVMDW Max Drawdown
-68.40%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RVMDW and SPY.
Company Overview
Revolution Medicines, Inc. Warrant
NASDAQ Global Select
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Leadership
- Mark A. Goldsmith
- IPO Date
- Feb 13, 2020
- Employees
- 616
- Street Address
- 700 Saginaw Drive
- Mailing
- Redwood City, CA, 94063
- Region
- Redwood City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 481 6801
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 17.2
Growth
- Revenue
- 0.0%
- EPS
- -66.2%
- Free Cash Flow
- -60.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -63.1%
- ROIC
- -56.8%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 7.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.